May 7 (Reuters) – Angelini Pharma said on Thursday that it will acquire Catalyst Pharmaceuticals in a $4.1 billion deal, marking the Italian drugmaker’s entry into the U.S. pharmaceutical market.
Under the agreement, Angelini will pay $31.5 in cash for each Catalyst share, representing a 3% premium over the company’s last closing price, according to LSEG-compiled data.
The acquisition will be supported by Blackstone funds and select international partners, while BNP Paribas will serve as global coordinator and underwriter for the transaction.
Founded in 2002, Florida-based Catalyst Pharmaceuticals specializes in the treatment of rare and difficult-to-treat conditions. The company’s U.S.-listed shares have climbed more than 30% so far this year, giving it a market value of $3.73 billion, according to the data.
The acquisition will establish Angelini Pharma as a “relevant global player in neurological rare diseases,” CEO Sergio Marullo di Condojanni said, adding that entering the U.S. market will help the drugmaker expand its scale and capabilities.
Angelini Pharma is the pharmaceutical division of Italy’s privately owned Angelini Industries, whose businesses span healthcare, consumer products, and industrial technology.
The group operates across 21 countries and reported annual turnover of 1.6 billion euros ($1.88 billion) in 2024, underpinned primarily by its healthcare division.
($1 = 0.8513 euros)
(Reporting by Ananya Palyekar in Bengaluru; Editing by Sumana Nandy and Sherry Jacob-Phillips)
Comments